Cipla Limited (CIPLA.NS)
| Previous close | 1,400.00 |
| Open | 1,400.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 1,398.15 - 1,426.00 |
| 52-week range | 896.85 - 1,519.00 |
| Volume | |
| Avg. volume | 1,512,396 |
| Market cap | 1.148T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 30.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 8.50 (0.61%) |
| Ex-dividend date | 21 July 2023 |
| 1y target est | N/A |
- PR Newswire
Cipla announces joint venture in the United States with Kemwell Biopharma and Manipal Education & Medical Group for global development and commercialisation of innovative Cell therapy products
Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products
- PR Newswire
Cipla Issues Voluntary Nationwide Recall of Six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) due to Container Defect
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla"), today announced that its wholly-owned subsidiary Cipla US is voluntarily recalling six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) manufactured in November 2021 to the consumer level.
